Member AUM
$75 trillion

Dechra Pharmaceuticals

LSE:DPH GB0009633180
Key Information
HQ:
United Kingdom
Market Cap:
$4.79bn
Primary Markets:
Europe & Russia, North America



Dechra Pharmaceuticals was assessed in 2022/2023 and in 2023/2024. In January 2024, the company was delisted from the London Stock Exchange.

Animal Pharmaceuticals Engagement

Analysis Breakdown




Revenue, Sales and Marketing Practices

Strategy, risk and reporting on antibiotics
Partial
Applying a consistent sales and marketing approach in line with best practice operating market
Low



Manufacturing and Production

Demonstrating effective management of antibiotic residues in manufacturing and production
Low



Research and Development

Defining alternatives to antibiotics
Low
Increasing availability and use of alternatives to antibiotics
NRD



Stewardship and Lobbying

Stewardship initiatives
Low
Lobbying and political expenditure
NRD



Company Engagement

Level of company engagement with FAIRR and investor signatories
Low

Members-only Content

To register as a member of the FAIRR network, please fill out the sign up form or if you need additional information on the FAIRR network, please contact investoroutreach@fairr.org.